News of Note—Dr. Reddy’s and FDA; Divi’s Labs plant cleared; SK Capital completes Perrigo API deal

newspaper
News of note from pharma manufacturing.

> Dr. Reddy’s in a filing said it will ask the FDA to reinspect its formulations plant in Duvvada in 2018. Announcement (PDF)

> India’s Divi’s Laboratories said in a filing with the Bombay Stock Exhange that the FDA has issued an Establishment Inspection Report for its Unit-II in Visakhapatnam, which had earlier received a Form 483 with six observations. Release (PDF)

> SK Capital has completed its $110 million buyout of Perrigo’s API business. Release | FiercePharma article